In this conversation, Dr. Radovich reflects on a landmark year for Caris, with 37 accepted poster presentations at ASCO — a true tour de force in the world of precision medicine. From bladder cancer breakthroughs to real-world evidence of therapy response through Caris’ molecular profiling, Dr. Radovich walks us through how data is finally delivering actionable, life-extending care for patients.
We also discuss:
- Why molecular profiling has become the bedrock of modern oncology
- A standout ASCO poster on tracking therapy response in bladder cancer using Caris tests
- The work of Caris Discovery, a dedicated team of 60+ advancing novel therapies grounded in tumor genomics
- The dramatic shift in cancer science — from an organ-based dogma to a molecular-first understanding of disease
- How AI is beginning to revolutionize oncology: from predicting recurrence and refining prognosis, to accelerating drug development
- The rise of genomic dependency in drug development — and the need to match therapies to each patient’s molecular fingerprint
Dr. Radovich describes this moment as a paradigm shift — a fusion of science fiction and clinical reality where the Star Trek era of precision oncology is no longer a dream, but something we’re living right now.
☕ Grab your favorite cup of tea and tune in to this inspiring episode of #HITeaWithGrace — a front-row seat to where cancer care is headed next.
👉 Don’t forget to like, comment, and subscribe for more fearless conversations on the future of health tech and clinical innovation.
#ASCO2025 #HITeaWithGrace #PrecisionOncology #CarisLifeSciences #MolecularProfiling #Genomics #AIinOncology #TargetedTherapies #BladderCancer #NovelTherapies #ClinicalInnovation #CancerSurvival #FutureOfMedicine #StarTrekTechMeetsCancerCare